Cell Origins of High-Grade Serous Ovarian Cancer
- PMID: 30424539
- PMCID: PMC6267333
- DOI: 10.3390/cancers10110433
Cell Origins of High-Grade Serous Ovarian Cancer
Abstract
High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates that STIC may serve as a precursor for HGSC in high-risk women carrying germline BRCA1 or 2 mutations. Yet not all STIC lesions appear to progress to clinical HGSCs, nor would all HGSCs arise from STIC lesions, even in high-risk women. Moreover, the clinical importance of STIC remains less clear in women in the general population, in which 85⁻90% of all HGSCs arise. Recently, increasing attention has been brought to the possibility that many potential precursor or premalignant lesions, though composed of microscopically-and genetically-cancerous cells, do not advance to malignant tumors or lethal malignancies. Hence, rigorous causal evidence would be crucial to establish that STIC is a bona fide premalignant lesion for metastatic HGSC. While not all STICs may transform into malignant tumors, these lesions are clearly associated with increased risk for HGSC. Identification of the molecular characteristics of STICs that predict their malignant potential and clinical behavior would bolster the clinical importance of STIC. Also, as STIC lesions alone cannot account for all HGSCs, other potential cellular origins of HGSC need to be investigated. The fallopian tube stroma in mice, for instance, has been shown to be capable of giving rise to metastatic HGSC, which faithfully recapitulates the clinical behavior and molecular aspect of human HGSC. Elucidating the precise cell(s) of origin of HGSC will be critical for improving the early detection and prevention of ovarian cancer, ultimately reducing ovarian cancer mortality.
Keywords: epithelial ovarian cancer; fallopian tube; high-grade serous carcinoma (HGSC); high-grade serous ovarian cancer (HGSOC); ovarian cancer; ovarian cancer origin; ovarian surface epithelium (OSE); serous tubal intraepithelial carcinoma (STIC).
Conflict of interest statement
Bast receives royalties for discovery of CA125 from Fujirebio Diagnostics Inc.
Figures
Similar articles
-
[Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].Zhonghua Bing Li Xue Za Zhi. 2017 Aug 8;46(8):542-547. doi: 10.3760/cma.j.issn.0529-5807.2017.08.005. Zhonghua Bing Li Xue Za Zhi. 2017. PMID: 28810294 Chinese.
-
Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.Gynecol Oncol. 2024 Aug;187:113-119. doi: 10.1016/j.ygyno.2024.05.010. Epub 2024 May 17. Gynecol Oncol. 2024. PMID: 38759517
-
Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.J Pathol. 2018 Nov;246(3):344-351. doi: 10.1002/path.5145. Epub 2018 Sep 27. J Pathol. 2018. PMID: 30043522
-
The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.Gynecol Oncol. 2019 Feb;152(2):426-433. doi: 10.1016/j.ygyno.2018.11.033. Epub 2018 Nov 30. Gynecol Oncol. 2019. PMID: 30503267 Review.
-
Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.Int J Clin Exp Pathol. 2014 Feb 15;7(3):848-57. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 24696706 Free PMC article. Review.
Cited by
-
Metastatic spread of serous ovarian carcinoma to the bilateral breasts: a rare presentation.BMJ Case Rep. 2022 Nov 24;15(11):e251721. doi: 10.1136/bcr-2022-251721. BMJ Case Rep. 2022. PMID: 36423949 Free PMC article.
-
Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.Cancer Biomark. 2019;26(4):471-479. doi: 10.3233/CBM-190528. Cancer Biomark. 2019. PMID: 31658047 Free PMC article.
-
Targeted Microchip Capillary Electrophoresis-Orbitrap Mass Spectrometry Metabolomics to Monitor Ovarian Cancer Progression.Metabolites. 2022 Jun 9;12(6):532. doi: 10.3390/metabo12060532. Metabolites. 2022. PMID: 35736465 Free PMC article.
-
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers.Cancer Prev Res (Phila). 2020 Mar;13(3):241-252. doi: 10.1158/1940-6207.CAPR-19-0184. Cancer Prev Res (Phila). 2020. PMID: 32132118 Free PMC article. Review.
-
Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.Cancer Res. 2023 May 2;83(9):1503-1516. doi: 10.1158/0008-5472.CAN-22-1821. Cancer Res. 2023. PMID: 36787106 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous